An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients

Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). Th...

Descripción completa

Detalles Bibliográficos
Autores: Krüger, Rejko|||0000-0003-4258-6241, Lingor, Paul, Doskas, Triantafyllos, Henselmans, Johanna M. L., Danielsen, Erik H., Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338, Stefani, Alessandro, Sensken, Sven-Christian, Parra, Juan Carlos, Onuk, Koray, Yegin, Ashley, Antonini, Angelo|||0000-0003-1040-2807
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:186277
Acceso en línea:https://ddd.uab.cat/record/186277
https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2
Access Level:acceso abierto
Palabra clave:Activities of daily living
Levodopa-carbidopa intestinal gel
Parkinson's disease
Percutaneous endoscopic gastrojejunostomy
Quality of life
id ES_f74a053a92425a5aa2b1a2a0b770e2e0
oai_identifier_str oai:ddd.uab.cat:186277
network_acronym_str ES
network_name_str España
repository_id_str
spelling An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease PatientsKrüger, Rejko|||0000-0003-4258-6241Lingor, PaulDoskas, TriantafyllosHenselmans, Johanna M. L.Danielsen, Erik H.Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338Stefani, AlessandroSensken, Sven-ChristianParra, Juan CarlosOnuk, KorayYegin, AshleyAntonini, Angelo|||0000-0003-1040-2807Activities of daily livingLevodopa-carbidopa intestinal gelParkinson's diseasePercutaneous endoscopic gastrojejunostomyQuality of lifeContinuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients. This prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily. Patients received LCIG via PEG-J for 16 h continuously. Effectiveness was assessed using Unified PD Rating Scale parts II and III, the Non-Motor Symptom Scale, and the PD Questionnaire-8. The mean (SD) treatment duration was 275 (157) days. Patients experienced significant improvement from baseline in activities of daily living at final visit (p < 0.05) as well as at months 3 and 6 (p < 0.0001). Patients also experienced significant improvements from baseline in quality of life and non-motor symptoms at all time points (p < 0.001 for all). Specifically, patients manifested significant improvements in mean change from baseline at every study visit in five of nine non-motor symptom score domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous. One-third of patients (32.8%) experienced an adverse event; 21.9% experienced a serious adverse event; 11.1% discontinued because of an adverse event. This study demonstrated significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of non-motor symptoms after treatment with LCIG. AbbVie Inc. The online version of this article (doi:10.1007/s12325-017-0571-2) contains supplementary material, which is available to authorized users.Universitat Autònoma de Barcelona 22017-01-0120172017-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/186277https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:1862772026-06-06T12:50:31Z
dc.title.none.fl_str_mv An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
title An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
spellingShingle An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
Krüger, Rejko|||0000-0003-4258-6241
Activities of daily living
Levodopa-carbidopa intestinal gel
Parkinson's disease
Percutaneous endoscopic gastrojejunostomy
Quality of life
title_short An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
title_full An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
title_fullStr An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
title_full_unstemmed An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
title_sort An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients
dc.creator.none.fl_str_mv Krüger, Rejko|||0000-0003-4258-6241
Lingor, Paul
Doskas, Triantafyllos
Henselmans, Johanna M. L.
Danielsen, Erik H.
Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
Stefani, Alessandro
Sensken, Sven-Christian
Parra, Juan Carlos
Onuk, Koray
Yegin, Ashley
Antonini, Angelo|||0000-0003-1040-2807
author Krüger, Rejko|||0000-0003-4258-6241
author_facet Krüger, Rejko|||0000-0003-4258-6241
Lingor, Paul
Doskas, Triantafyllos
Henselmans, Johanna M. L.
Danielsen, Erik H.
Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
Stefani, Alessandro
Sensken, Sven-Christian
Parra, Juan Carlos
Onuk, Koray
Yegin, Ashley
Antonini, Angelo|||0000-0003-1040-2807
author_role author
author2 Lingor, Paul
Doskas, Triantafyllos
Henselmans, Johanna M. L.
Danielsen, Erik H.
Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
Stefani, Alessandro
Sensken, Sven-Christian
Parra, Juan Carlos
Onuk, Koray
Yegin, Ashley
Antonini, Angelo|||0000-0003-1040-2807
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Activities of daily living
Levodopa-carbidopa intestinal gel
Parkinson's disease
Percutaneous endoscopic gastrojejunostomy
Quality of life
topic Activities of daily living
Levodopa-carbidopa intestinal gel
Parkinson's disease
Percutaneous endoscopic gastrojejunostomy
Quality of life
description Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients. This prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily. Patients received LCIG via PEG-J for 16 h continuously. Effectiveness was assessed using Unified PD Rating Scale parts II and III, the Non-Motor Symptom Scale, and the PD Questionnaire-8. The mean (SD) treatment duration was 275 (157) days. Patients experienced significant improvement from baseline in activities of daily living at final visit (p < 0.05) as well as at months 3 and 6 (p < 0.0001). Patients also experienced significant improvements from baseline in quality of life and non-motor symptoms at all time points (p < 0.001 for all). Specifically, patients manifested significant improvements in mean change from baseline at every study visit in five of nine non-motor symptom score domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous. One-third of patients (32.8%) experienced an adverse event; 21.9% experienced a serious adverse event; 11.1% discontinued because of an adverse event. This study demonstrated significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of non-motor symptoms after treatment with LCIG. AbbVie Inc. The online version of this article (doi:10.1007/s12325-017-0571-2) contains supplementary material, which is available to authorized users.
publishDate 2017
dc.date.none.fl_str_mv 2
2017-01-01
2017
2017-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/186277
https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2
url https://ddd.uab.cat/record/186277
https://dx.doi.org/urn:doi:10.1007/s12325-017-0571-2
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424869253316608
score 15,300719

Similares en LA Referencia